Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 18/20 | 0.36 |
| ▸ | CA2 | P00918 | 18/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3812152 | 0.91 | NOS3 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| Water SCHEMBL21810558 | 0.89 | NOS3 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL346040 | 0.86 | NOS3 (0.36) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL21404061 | 0.86 | CA1 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL941222 | 0.86 | ALDH1A1 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL584167 | 0.84 | NOS3 (0.35) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL5345186 | 0.84 | CA1 (0.36) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL449032 | 0.82 | NOS3 (0.34) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL21404095 | 0.82 | NOS3 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL29175400 | 0.82 | NOS3 (0.38) | NOS3NOS1NOS2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007146086-A1 | CREATINE PRODRUGS, COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070281996-A1 | Creatine prodrugs, compositions and uses thereof | XENOPORT, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281996-A1 | Creatine prodrugs, compositions and uses thereof | CKMT1A; CKMT1B, PYGM, TNNI3 | NOS3 1845/4885NOS1 2190/4885NOS2 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.